Moderate cognitive disorder in cerebrovascular diseases: ways to prevent further progression
O.V. Kolokolov, A.Yu. Maleina, E.V. Lukina

Saratov Razumovsky State Medical University

The article discusses the actual problem of the timely detection and adequate therapy of a moderate cognitive disorder (MCD) and a sleep disorder, which onset impinge on patients of young and middle age with hypertension and other circulatory system diseases. Criteria for clinical diagnosis, neuropsychological approaches, neuroimaging methods and biomarkers are listed to determine the type of MCD and etiology of the disease. Special attention is paid to cognitive disorder associated with cerebrovascular diseases (CVD) — vascular cognitive disorder. There are data on the relationship between the sleep disorders, depression and MCD. It was emphasized that the correction of sleep disorders and depression in some cases allows achieving the recovery of cognitive functions. It was stated that the treatment of MCD, which onset is in young- and middle-aged patients, largely depends on the etiology of the disease. The data on the use of the drug Divaza in patients younger than 65 years old with CVD are presented. The use of the drug Divaza, which has an antihypoxant, antioxidant, nootropic and angioprotective effect, in combination with basic therapy allows to restore the quality of night sleep and reduce the severity of MCD.

Key words: cognitive functions, dementia, cognitive disorder, cerebrovascular disease, chronic cerebral ischemia, discirculatory encephalopathy, neuroimaging, biomarkers, protein S-100, Divasa.
For citation: Kolokolov O.V., Maleina A.Yu., Lukina E.V. Moderate cognitive disorder in cerebrovascular diseases: ways to prevent further progression // RMJ. 2018. № 12(I). P. 3–9.